Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 0

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
                                       224,631                  485,058  
  Net                                                                                                         1,045                 ( 59,189  
  Cash                                                                                                          716                  121,037  
  Cash                                                                         $                              1,761      $            61,848  
  Supplemental                                                                                                                                
  Cash                                                                                                                                        
  Interest                                                                     $                                  -      $                 -  
  Income                                                                       $                                  -      $                 -  
  Supplemental                                                                                                                                
  Common                                                                       $                             20,000      $                 -  
  Conversion                                                                   $                            232,111      $                 -  

The
accompanying notes are an integral part of the consolidated financial statements.

   6  

REGEN
BIOPHARMA, INC.

Notes
to Condensed Consolidated Financial Statements

As
of June 30, 2025

1. ORGANIZATION

The
Company was organized April 24, 2012 under the laws of the State of Nevada.

The
Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities
up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license
those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The
Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation
for oncology applications and immune cell suppression for autoimmune disease.

The
Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval
from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing
and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products
or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications
up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to
sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company
can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such
sale or license will be on terms favorable to the Company.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Going
Concern Matters